Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 65,889	$ 84,833
Prepaid expenses and other current assets	1,676	3,513
Total current assets	67,565	88,346
Operating lease asset, net	832	768
Goodwill	48,648	48,648
In-process research and development	32,386	32,386
Other assets	155	400
Total assets	149,586	170,548
Current liabilities:
Accounts payable	3,859	1,813
Current operating lease liability	378	369
Accrued expenses and other liabilities	2,043	2,219
Total current liabilities	6,280	4,401
Deferred tax liability	1,752	1,752
Non-current operating lease liability	461	400
Total liabilities	8,493	6,553
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.001 par value, 200,000,000 shares authorized at March 31, 2022 and December 31, 2021; 13,756,788 and 14,306,788 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	14	14
Additional paid-in capital	285,560	278,880
Accumulated deficit	(144,481)	(114,899)
Total stockholders’ equity	141,093	163,995
Total liabilities and stockholders’ equity	149,586	170,548
Series X1 Non-voting Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value
Series X Non-voting Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value

In-process research and development.

No definition available.

Name:	eldn_InProcessResearchAndDevelopment
Namespace Prefix:	eldn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).